Who is sponsoring NCT03527199?

NCT03527199 is sponsored by Medhat Osman.

What drugs are being tested in NCT03527199?

Interventions in NCT03527199: Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC).

What condition does NCT03527199 study?

NCT03527199 studies Patients With Prostate Cancer.

Is NCT03527199 still recruiting?

NCT03527199 is currently completed. Last updated 11 April 2023.

Last reviewed 2023-04-11 · How we verify

NCT03527199

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prostate Cancer Patients With Biochemical Recurrence

Completed Last updated 11 April 2023

What this trial tests

trial testing Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC) in Patients With Prostate Cancer in 65 participants. Completed in 10 April 2023.

Timeline

18 December 2018

Primary endpoint
10 April 2023

10 April 2023

Quick facts

Lead sponsor	Medhat Osman
Status	Completed
Study type	OBSERVATIONAL
Enrollment	65
Start date	18 December 2018
Primary completion	10 April 2023
Estimated completion	10 April 2023
Sites	1 location across United States

Drugs / interventions tested

Pelvic CT or MRI + MDP bone scan + or - 18F-NaF PET/CT(SOC)

Conditions studied

Patients With Prostate Cancer — all drugs for Patients With Prostate Cancer →

Sponsor

Medhat Osman

Who can join

Adults 18 to 89, male only, with Patients With Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of detection rate of 18F-Fluciclovine compared to current standard of care imaging techniques within 30 days of the standard of care imaging study and a 6 month phone follow-up

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03527199 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medhat Osman
Last refreshed: 11 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03527199.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing